Zoledronic acid can temporarily decrease PTH‐dependent hypercalcemia and is not only used in the treatment of osteoporosis because of its anti‐bone‐resorptive effects but also for the treatment of bone metastases, usually given in 4‐week intervals.23, 24. This evidence concerns the gene PTH and hypercalcemia disease.